Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
Center for Diabetes, Academic Specialist Center, Region Stockholm, Sweden
Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Physiology, Capio St Görans Hospital, Stockholm, Sweden
Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden
Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden
Corresponding author. Tel: +46-73-7142987. E-mail: [email protected]
Prior presentation: Parts of this study were presented as oral presentation at the 56th EASD Annual Meeting 2020, 22–25 September 2020.
Conflict of interest: The authors declare that they have no conflicts of interest concerning this study. S.K. reports personal fees from Astra Zeneca, Boehringer Ingelheim, and Novo Nordisk. A.N. reports personal fees from Astra Zeneca, MSD, Boehringer Ingelheim, Lilly, and Novo Nordisk. L.L.-H. reports personal fees from Novo-Nordisk. L.F. reports personal fees from Bayer, Boehringer Ingelheim, BMS, Pfizer, and Sanofi. P.L. reports personal fees from Boehringer Ingelheim, Sanofi, and Novo Nordisk.
Received February 06, 2022
Received in revised form April 24, 2022
Accepted May 11, 2022
Revised June 07, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]
